Rare cancers: the role of patient advocates in raising awareness

By Kathy Oliver
International Brain Tumour Alliance (IBTA)
14 January 2021
Disclosure of Interests (2005 to date)

International Brain Tumour Alliance (IBTA)

The IBTA has, since its establishment in 2005, received funding support from AbbVie, Accuray, Antisense Pharma, Apogenix, Archimedes, Ark Therapeutics, Astra Zeneca, Bayer, Boehringer Ingelheim, Brain Tumor Network (USA), Brain Tumor Resource and Information Network (USA), Bristol-Myers Squibb (BMS) Celldex Therapeutics, Crusade, Dijon Designs (UK), Elekta, Eli Lilly, Gerry & Nancy Pencer Brain Trust (Canada), Gosling Foundation (UK), GlaxoSmithKline (GSK), Ivy Foundation (USA), Lilly, Link Pharmaceuticals, MagForce, Medac, Merck Serono, Merck, MGI Pharma, MSD Oncology, NeoPharm, Neuroendoscopy (Australia), Northwest Biotherapeutics, Novartis, Novocure, Pediatric Brain Tumor Foundation (USA), Pfizer, Photonamic, Roche, Schering-Plough (Global), Sontag Foundation (USA), Spink (UK), to-BBB, Vane Percy (UK), VBL Therapeutics and the Wallerstein Foundation (USA).

Patient Advisory Boards: Novartis, Bristol-Myers Squibb, AbbVie, GSK, Lilly, Novocure

Committees/Projects: EURACAN, All.Can, ECCO Patient Advisory Committee, Rare Cancers Europe, GLIOTRAIN, EORTC SISAQOL project, SNO Guidelines Committee, WECAN, INSERT, NCRI Brain Tumour Subgroup on Palliative and Supportive Care, EANO Palliative and Supportive Care Task Force, NCI-CONNECT

For full details of the IBTA’s sponsorship policy, and comprehensive details of our funding organisations, please see our website at www.theibta.org
Rarity…

A rare 76 carat diamond valued at US $15 million

Rare kangaroo stamps (Australia)

Rare aurora borealis butterfly (South America)

A rare golden snub-nosed monkey (China)
Painting by M’Liz Keefe (USA), sister of a young glioblastoma brain tumour patient
5.1 million Europeans are affected by a rare cancer*

And if every person with a rare cancer in Europe stood next to each other holding hands, then 5.1 million people would stretch 4,000 kilometres which is the entire breadth of Australia, from Perth to Sydney AND beyond.

* RARECARENet
Rare cancers = an incidence of less than 6 people in 100,000 per year *

* Rare Cancers Europe: https://www.rarecancerseurope.org/
There are nearly 200 different types of rare cancers.

Distribution of “families” of rare cancers

Illustration courtesy of Rare Cancers Europe
Together, rare cancers represent about 24% of all cancer cases diagnosed in the European Union each year, including rare adult solid tumours (13%) and rare haematological cancers (8%) as well as all childhood cancers (1%).
Some of the challenges of rare cancers…

- Prevention and screening mostly irrelevant
- Late or incorrect diagnosis
- Lack of information and patient groups
- Widespread, small populations of patients
- Shortage of local medical expertise
- Incomplete registries and tissue banks
- Methodological barriers (in traditionally-designed clinical trials)
- Not enough clinical trials for rare cancers
- Regulatory barriers
- Reimbursement challenges for treatments
- Inequitable access to therapies and care
- Stigma

Rare cancer (five year relative) survival is worse at 48.5% than common cancer at 63.4%. *

For rare cancers, there are four relevant ERNs:

- **ERN PAEDCAN**
- **EuroBloodNet**
- **EURACAN**

**EURACAN**

*European network for Rare adult solid Cancer*
The background on ePAGs

EURORDIS established ePAGs and acts as a coordinator of them across the ERNs. Representatives of ePAGS are selected based on stringent criteria:

- cancer patient advocacy track record
- knowledge of European healthcare policies and institutions
- working experience in EU healthcare projects and with clinicians, researchers, regulators and others

The role of ePAGs

- ensure that care is patient-centred and there is respect for patients’ rights and choice
- ensure transparency in quality of care, safety standards, clinical outcomes and treatment options
- ensure that ethical issues for patients are addressed
- contribute to the development of patient information, policy documents, good practice, care pathways and guidelines
- advise on planning, monitoring and evaluation of ERN initiatives
- Help disseminate information about ERNS to patient and medical communities
Patient advocacy and awareness-raising addresses unmet needs and gaps in healthcare provision so that optimal treatment, care and support are delivered to rare cancer patients, their caregivers and families.
Why are rare cancer patient perspectives important?

If your life or your quality of life depends on the results of a decision, then you need to be at the heart of that decision-making process.

- Patients are no longer passive recipients of medical care
- Patient engagement creates a win-win situation for people, healthcare services and policy
- Patients may throw an important, different light on conventional wisdom
The patient advocacy perspective brings:

- Value
- Knowledge
- Experience
- Change
Patients’ rights activism in the United States in the 1970s led to widespread social action and healthcare system reform.
The HIV/AIDS movement in the 1980s and 1990s brought massive change in the medical research paradigm.

A 1985 protest in New York City, the hub of the AIDS epidemic and the corresponding art movement. Source: https://mashable.com/2016/10/26/aids-epidemic-study/
What does rare cancer patient advocacy look like?

Patient advocacy upholds the notion that every patient living with a rare cancer should be valued, respected, listened to and as involved with their own care as they wish to be.
What does cancer patient advocacy look like?

- Liaise between patients and their medical professionals
- Defend patients’ rights
- Lobby government for policy change
- Raise funds for research and support
- Build knowledge and capacity in patient communities
- Address the challenges of patient-centred care
- Provide educational materials
- Support and empower patients, their families and caregivers
- Raise awareness
- Help reduce anxiety, uncertainty and fear
- Sustain hope
Training for cancer patient advocates

RCE-ESO-ESMO Training Course for Rare Cancer Patient Advocates

Evidence-Based Advocacy Course

WECAN Science
## What can you do for your rare cancer community?

<table>
<thead>
<tr>
<th><strong>Raise Awareness</strong></th>
<th>Raise awareness of rare cancers on a national policy level in your country to ensure that European Reference Networks such as EURACAN are built on the strong foundations of national rare disease and rare cancer plans.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Support</strong></td>
<td>Support efforts for new national centres of expertise in your country for rare cancers.</td>
</tr>
<tr>
<td><strong>Know</strong></td>
<td>Get to know the healthcare professionals in your country who are dealing with the rare cancer for which you want to raise awareness.</td>
</tr>
<tr>
<td><strong>Respect</strong></td>
<td>Respect the challenges that healthcare professionals have every single day.</td>
</tr>
<tr>
<td><strong>Build bridges</strong></td>
<td>Help to break down silos and instead build bridges between the stakeholders in your rare cancer field. Identify unmet needs and gaps in healthcare provision.</td>
</tr>
<tr>
<td><strong>Learn</strong></td>
<td>Learn about national healthcare policies for rare diseases in your country.</td>
</tr>
<tr>
<td><strong>Don’t give up</strong></td>
<td>Don’t give up – you WILL make a difference.</td>
</tr>
</tbody>
</table>
Rare cancers...we’re getting there